An investment analyst by background, Jennie has been leading investor relations, corporate affairs, client marketing and corporate responsibility at senior management level in world-leading companies. Her experience, gained over 30 years in FTSE 100 companies and global investment banks, plays well to Disruptive III investment themes spanning three key global sectors: financial services, healthcare and energy. She has significant experience in managing stakeholders through complex and challenging strategic events such as M&A and strategic change, in high profile, global industries, including Astra Zeneca, Glaxo SmithKline and Deutsche Bank.
Wilhelm von Stotzingen joined the Disruptive Capital Finance team to lead several Swiss based projects. Wilhelm has over 10 years financial project work experience within Private Equity and the consumer goods sector. In his last role, he was Investment Director at Steinbock Mittelstandsbeteiligungen Management AG in Zürich where he was responsible for Deal Flow, Investment Analysis and Portfolio Controlling including operational and strategic value creation. From 2010 to 2015, Wilhelm held various management positions at Procter & Gamble in Geneva. As an entrepreneur he co-founded and runs a philanthropic company in Kenya.
Wilhelm holds a Bachelor’s degree in Business Administration from the University of St. Gallen and is finalizing the Global Executive MBA at the IE Business School.
News from Disruptive Capital GP Limited
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc
21 May 2021Brooklyn, NY – May 21, 2021 – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced...
One of the UK’s largest traffic signal maintenance contracts awarded to Telent
18 May 2021Warwick, U.K., 18 May 2021 – Critical digital infrastructure specialist Telent has been awarded a contract to maintain West Yorkshire’s traffic signals, the largest contract of its kind. Telent is responsible for the maintenance, fault rectification and repair of 1,600 sites over a geographical area covering 2,029 km². The sites include assets such as traffic signals, lights, vehicle detectors and monitors, and other roadside assets.
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy
11 May 2021BROOKLYN, N.Y. – May 11, 2021 – Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced...
Brooklyn Immunotherapeutics (BTX) Soars After Entering Into An Agreement with Lincoln Park Capital Fund
03 May 2021Brooklyn Immunotherapeutics (BTX) entered into a Purchase Agreement and a Registration Rights Agreement on April 26, 2021 with Lincoln Park Capital Fund...
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform
29 April 2021Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders...